NexEos Bio has two development programs based on eMBP1, an eosinophil degranulation product, which is a central actor driving inflammation: 1) a diagnostic that binds to eMBP1 to detect eosinophil-driven inflammation, initially targeting Eosinophilic Esophagitis (EoE); 2) a therapeutic aimed at neutralizing eMBP1 to reduce inflammation and control clinical outcomes, initially targeting eosinophil-driven eye conditions.
The company’s lead diagnostic (NDX-3315) would be the first, non-invasive and visual imaging agent to diagnose and monitor EoE (versus current diagnostic standard of endoscopy with biopsy). This approach provides an easier, safer, and cost-effective solution for patients and a more sensitive diagnostic for physicians. NDX-3315 has demonstrated proof of concept and established safety in EoE patients. This program fills an important unmet need, has been granted Orphan Drug Designation for EoE, and has an approved IND. The de-risked safety and efficacy give NDX-3315 an unusually high probability of success.